An investigation has been initiated by the Law Offices of Howard G. Smith concerning Allarity Therapeutics, Inc. (“Allarity” or the “Company”) investors over potential breaches of federal securities regulations in relation to recent developments.

Disclosure of Alleged Wrongdoings

On July 22, 2024, Allarity Therapeutics made an unsettling revelation. The company disclosed the reception of a crucial Wells Notice from the U.S. Securities and Exchange Commission. This notice pertained to the Company’s purported inaccurate statements regarding discussions with the U.S. Food and Drug Administration concerning the New Drug Application (NDA) for its drug, Dovitnib, which had been submitted back in 2021. Moreover, the disclosure mentioned that three former officers of Allarity Therapeutics also received Wells Notices. These notices outlined that the SEC Staff has preliminarily recommended a potential enforcement action against the Company for purported violations of federal securities laws.

Investor Caution Advised

For investors who have vested interests in Allarity Therapeutics, vigilance is key. Seeking further information on these claims or inquiries regarding rights and involvement in these matters is advised. To elaborate on the subject matter or discuss concerns stemming from this announcement, individuals are encouraged to get in touch with Howard G. Smith, Esquire, at the Law Offices of Howard G. Smith. Additionally, investors can visit the mentioned website or contact them through the specified telephone number or email address.

Legal Disclaimer

As a note of caution, it is essential to acknowledge that this press release may be deemed Attorney Advertising in specific jurisdictions based on pertinent laws and ethical standards.

View source version on businesswire.com: Click here for the source article